Chondroitin - instructions for use, dose, side effects, contraindications

Description:Hard gelatin capsules № 0 of white color. The contents of the capsules are a powder or compacted mass from white with a yellowish scum to a light yellow color, disintegrating when pressed with a glass rod.

Pharmacotherapeutic group:Reparation of tissue stimulant.

ATX: & nbsp

M.01.A.X.25 Chondroitin sulfate

Pharmacodynamics:Chondroitin sulfate sodium (chondroitin sulfate) - a high molecular weight mucopolysaccharide, which slows the resorption of bone tissue and reduces the loss of calcium ions (Ca2 +). It improves the phosphorus-calcium metabolism in the cartilaginous tissue, accelerates the processes of its restoration, inhibits the processes of degeneration of the cartilaginous and connective can. Suppresses enzymes that cause damage to cartilaginous tissue,stimulates the synthesis of glycosaminoglycans, promotes the regeneration of the articular bag and the cartilaginous surfaces of the joints, increases the production of intra-articular fluid. Due to its structural affinity for heparin, it prevents the formation of fibrin clots in the synovial and subchondral microcirculatory bed. Reduces soreness and increases the mobility of affected joints. Slows the progression of osteoarthritis and osteochondrosis, alleviates the symptoms of the disease and reduces the need for non-steroidal anti-inflammatory drugs (NSAIDs). The therapeutic effect persists for a long time after the end of the course of treatment.

Pharmacokinetics:

Suction

Boles of 70% of chondroitin sulfate are absorbed in the digestive tract. Bioavailability of the drug is 13%.

With a single admission of the mediotherapy dose, the maximum concentration (C_max) in blood plasma is achieved after 3-4 hours, in the synovial fluid in 4-5 hours.

Distribution

Chondroitin sulfate accumulates mainly in the cartilaginous tissue (C_max in articular cartilage is reached after 48 hours); synovium is not an obstacle to its penetration into the cavitythe joint.

Metabolism

It is metabolized by desulfurization.

In the introduction

It is excreted by the kidneys within 24 hours.

Indications:Degenerative and dystrophic diseases of the joints and spine: treatment and prevention of osteochondrosis, osteoarthrosis of peripheral joints and spine.

Contraindications:

- Hypersensitivity to chondroitin sulfate or other components of the drug;

- lactose intolerance, lactase deficiency, glucose-galactose malabsorption;

- Children under 15 years of age (effectiveness and safety not established);

- Pregnancy;

- the period of breastfeeding.

Carefully:bleeding and a tendency to bleeding; thrombophlebitis.

Pregnancy and lactation:

Pregnancy

Adequate and strictly controlled clinical studies on the safety of the drug in pregnant women have not been conducted, so the drug should not be used during pregnancy.

Breastfeeding period

For the period of treatment with Chondroitin, breastfeeding should be discontinued.

Dosing and Administration:

Inside, washing down with water.

Adults appoint 750 mg (3 capsules) 2 times a day for the first 3 weeks, then 500 mg (2 capsules) 2 times a day.

The recommended duration of the initial course of treatment is 6 months, the period of the drug after its withdrawal is 3-5 months, depending on the location and stage of the disease, the duration of repeated courses of treatment is established by the doctor.

Side effects:

Classification of the incidence of adverse events according to recommendations

World Health Organization (WHO):

very often> 1/10;

often from> 1/100 to <1/10;

infrequently from> 1/1000 to <1/100;

rarely from> 1/10000 to <1/1000;

very rarely <1/10000, including individual messages;

the frequency is unknown - it is not possible to establish the frequency of occurrence from the available data.

Disorders from the gastrointestinal tract: rarely - nausea, vomiting, diarrhea.

Disorders from the immune system: rarely - allergic reactions (hives, erythema, skin itching).

Overdose:

Symptoms

In rare cases, symptoms of an overdose on the part of the gastrointestinal tract are possible: nausea, vomiting, diarrhea; with prolonged intake of excessively high doses (over 3.0 g), hemorrhagic eruptions are possible.

Treatment

Conduction of symptomatic therapy, gastric lavage.

Interaction:With the simultaneous use of the drug Chondroitin with other drugs may increase the effect of indirect anticoagulants, antiaggregants, fibrinolytics, which requires more frequent monitoring of blood coagulation in a joint application.

Special instructions:

Caution should be given to patients with bleeding, as well as patients with a tendency to bleeding.

The drug Chondroitin is compatible with NSAIDs and glucocorticosteroids.

Effect on the ability to drive transp. cf. and fur:Does not affect the ability to drive and other mechanisms.

Form release / dosage:Capsules 250 mg.

Packaging:

10 or 20 capsules in a planar cell packaging made of polyvinylchloride film and aluminum foil.

3, 5 or 6 contour cell packs of 10 capsules or 5 out-of-round cell packs of 20 capsules together with instructions for use in a pack of cardboard.

Storage conditions:Store in a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:

2 years.

Do not use after expiry date.

Terms of leave from pharmacies:Without recipe

Registration number:LS-001589

Date of registration:02.02.2011

The owner of the registration certificate:VERTEKS, AO VERTEKS, AO Russia

Manufacturer: & nbsp

VERTEKS, AO Russia

Information update date: & nbsp28.09.2015

Illustrated instructions

Instructions

Chondroitin (Chondroitin)